0001683168-24-001367.txt : 20240307 0001683168-24-001367.hdr.sgml : 20240307 20240307063011 ACCESSION NUMBER: 0001683168-24-001367 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240306 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avid Bioservices, Inc. CENTRAL INDEX KEY: 0000704562 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953698422 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32839 FILM NUMBER: 24728061 BUSINESS ADDRESS: STREET 1: 14191 MYFORD ROAD CITY: TUSTIN STATE: CA ZIP: 92780 BUSINESS PHONE: 714.508.6100 MAIL ADDRESS: STREET 1: 14191 MYFORD ROAD CITY: TUSTIN STATE: CA ZIP: 92780 FORMER COMPANY: FORMER CONFORMED NAME: PEREGRINE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20001109 FORMER COMPANY: FORMER CONFORMED NAME: TECHNICLONE CORP/DE/ DATE OF NAME CHANGE: 19970924 FORMER COMPANY: FORMER CONFORMED NAME: TECHNICLONE INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 8-K 1 avid_8k.htm CURRENT REPORT
false 0000704562 0000704562 2024-03-06 2024-03-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 6, 2024

 

 

 

AVID BIOSERVICES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 001-32839 95-3698422
(State of other jurisdiction
of incorporation)		 (Commission
File Number)		 (IRS Employer
Identification No.)

 

14191 Myford Road, Tustin, California 92780

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (714) 508-6100

 

__________________________________

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
☐Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class Trading Symbol Name of each exchange on which registered
Common Stock, $0.001 par value per share CDMO The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☐   Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 6, 2024, Avid Bioservices, Inc. (the “Company”) issued a press release announcing certain preliminary financial results as of and for its third quarter and nine months ended January 31, 2024. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

The information in this Item 2.02 and Exhibit 99.1 hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing. 

 

Item 3.02 Unregistered Sales of Equity Securities.

 

On March 6, 2024, the Company entered into separate privately negotiated subscription agreements with certain investors to sell and issue $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). The sale and issuance of the 2029 Notes will be effected in reliance on Section 4(a)(2) of the Securities Act (the “Offering”). All of the purchasers of the 2029 Notes are “qualified institutional buyers” as that term is defined in Rule 144A of the Securities Act. The Company anticipates that the closing of the Offering will occur on or about March 12, 2024, subject to customary closing conditions.

 

The 2029 Notes will represent senior unsecured obligations of the Company and will pay interest semiannually in arrears on each of March 1 and September 1, commencing on September 1, 2024, at a rate of 7.00% per annum. The 2029 Notes will mature on March 1, 2029, unless earlier converted or repurchased. The 2029 Notes will be convertible at the option of the holders in certain circumstances into cash, shares of the Company’s common stock or a combination of cash and the Company’s common stock, at the Company’s election. The initial conversion rate is 101.1250 shares of the Company’s common stock per $1,000 principal amount of 2029 Notes, which is equivalent to an initial conversion price of approximately $9.89 per share, and will be subject to customary anti-dilution adjustments. The Company may not redeem the 2029 Notes prior to the maturity date.

 

The Company expects to use a portion of the net proceeds from the Offering (i) to repurchase for cash a portion of the Company’s 1.250% Exchangeable Senior Notes due 2026 (“2026 Notes”) in privately negotiated transactions from certain noteholders and (ii) to the extent there are 2026 Notes outstanding after such repurchases, to repay in full any remaining outstanding 2026 Notes by depositing the required payoff amount with the trustee under the indenture for the 2026 Notes. As described in more detail in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2024, all of the 2026 Notes have been accelerated and have become due and payable pursuant to an acceleration notice.

 

The Company issued a press release to announce the Offering on March 6, 2024 and issued a press release to announce the pricing of the Offering on March 6, 2024, copies of which are filed as Exhibit 99.2 and Exhibit 99.3 to this Current Report, respectively.

 

This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer to sell, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. These securities have not been registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States or to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state laws.

 

Forward-Looking Statements

 

Statements in this report, which are not purely historical, including statements regarding the timing, size and expected completion of the offering of 2029 Notes, the use of proceeds from the Offering, and other statements that are not statements of historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, those related to market and other conditions; the risk that the conditions to the closing of the Offering are not satisfied; and other risks and uncertainties that are described in the Risk Factors section of our annual report on Form 10-K for the fiscal year ended April 30, 2023, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this report, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this report except as may be required by law.

 

 

 2 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

Number

 

99.1 Press Release Announcing Certain Preliminary Financial Results, dated March 6, 2024
99.2 Press Release Announcing Convertible Note Offering, dated March 6, 2024
99.3 Press Release Announcing Pricing of Convertible Note Offering, dated March 6, 2024
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 

 

 

 3 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AVID BIOSERVICES, INC.  
       
       
Date: March 7, 2024 By: /s/ Daniel R. Hart  
    Daniel R. Hart  
    Chief Financial Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 4 

 

 EX-99.1 2 avid_ex9901.htm PRESS RELEASE ANNOUNCING CERTAIN PRELIMINARY FINANCIAL RESULTS, DATED MARCH 6, 2024

Exhibit 99.1

 

 

Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024

 

TUSTIN, Calif., March 6, 2024 -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024.

 

The company expects results in the third quarter of fiscal 2024 to include:

 

Revenues & Backlog

 

·Revenues for the third quarter of fiscal 2024 were $33.8 million, representing an 11% decrease as compared to revenues of $38.0 million recorded in the same prior year period and a 33% increase as compared to revenues of $25.4 million recorded in the second quarter of fiscal 2024. For the first nine months of fiscal 2024, revenues were $96.9 million, a decrease of approximately 11% compared to $109.5 million in the same prior year period. The decrease in revenues for the third quarter and nine months ended January 31, 2024 compared to the same prior year periods was primarily attributed to fewer manufacturing runs and a reduction in process development services from early-stage customers. Additionally, the first nine months revenues were also impacted by a reduction of revenue for changes in estimated variable consideration under a contract where uncertainties have been resolved.

 

·The company’s commercial team signed multiple new orders during the third quarter of fiscal 2024, totaling approximately $41 million net, and resulting in record high revenue backlog of $206 million, representing an increase of 17% compared to $176 million at the end of the same quarter last year. These orders span a broad range of the company’s capabilities and are primarily from later-stage projects. The company anticipates a significant amount of its backlog will be recognized as revenue over the next five fiscal quarters.

 

Gross Profit

 

·Gross profit for the third quarter of fiscal 2024 was $2.4 million (7% gross margin), compared to $9.8 million (26% gross margin) in the third quarter of fiscal 2023 and a gross loss of $4.7 million (negative 18% gross margin) in the second quarter of fiscal 2024. Gross profit for the first nine months of fiscal 2024 was $1.8 million (2% gross margin), compared to a gross profit of $23.1 million (21% gross margin) for the same period during fiscal 2023. The decrease in gross margin for the three and nine months ended January 31, 2024 compared to the same prior year periods was primarily driven by fewer manufacturing runs, a reduction in process development services from early-stage customers, and an increase in our costs related to expansions of both the company’s capacity and technical capabilities.  Gross margins during the nine months ended January 31, 2024, were also impacted by a reduction of revenue for changes in estimated variable consideration under a contract where uncertainties have been resolved, a terminated project relating to the insolvency of one of the company’s smaller customers, and a delay in the ability to recognize revenues of a customer product pending the implementation of a process change.

 

Selling, General and Administrative (SG&A) Expenses

 

·SG&A expenses for the third quarter of fiscal 2024 were $6.4 million, a decrease of 10% compared to $7.1 million recorded for the third quarter of fiscal 2023 and a decrease of 3% compared to $6.6 million recorded for the second quarter of fiscal 2024. SG&A expenses for the first nine months of fiscal 2024 were $19.2 million, a decrease of approximately 6% compared to $20.3 million recorded in the same prior year period. The decrease in SG&A for both the three and nine months ended January 31, 2024 compared to the same prior year periods was primarily due to decreases in compensation and benefit related expenses, and consulting fees.

 

Operating Income (Loss)

 

·Operating loss for the third quarter of fiscal 2024 was $4.0 million, a decrease compared to operating income of $2.7 million recorded for the third quarter of fiscal 2023 and an increase compared to an operating loss of $11.2 million recorded for the second quarter of fiscal 2024. Operating loss for first nine months of fiscal 2024 was $17.4 million compared to operating income of $2.8 million for the first nine months of fiscal 2023. The decrease in operating income for the three and nine months ended January 31, 2024 compared to the same prior year periods was driven by a decrease in gross profit partially offset by reduced SG&A.

 

 

   

 

 

Other Items

 

·The company is maintaining revenue guidance for full fiscal year 2024 of $137mm to $147mm.

 

·On January 31, 2024, Avid reported cash and cash equivalents of $30.7 million, compared to $38.5 million on April 30, 2023.

 

·During the quarter, Avid marked the completion of its cell and gene therapy (or CGT) facility, representing the final step in a three-year expansion program that has dramatically increased the company’s service offerings and revenue generating capacity. Avid estimates that its combined mammalian and CGT facilities now have a total revenue generating capacity of up to approximately $400mm annually.

 

About Avid Bioservices, Inc.

 

Avid Bioservices (NASDAQ:CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

 

Forward-Looking Statements

 

Statements in this press release, which are not purely historical, including statements regarding Avid Bioservices' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, but not limited to, the risk the company may experience delays in engaging new customers, the risk that the company may not be successful in executing customers projects, the risk that changing economic conditions may delay or otherwise adversely impact the realization of the company’s backlog, the risk that the company may not be able to convert its backlog into revenue within the contemplated time periods, the risk that the company may experience technical difficulties in completing customer projects due to unanticipated equipment and/or manufacturing facility issues which could result in projects being terminated or delay delivery of products to customers, revenue recognition and receipt of payment or result in the loss of the customer, the risk that one or more existing customers terminates its contract prior to completion or reduces or delays its demand for development or manufacturing services which could adversely affect guided fiscal 2024 revenues, the risk that our reported financial results may differ from the preliminary financial results included herein as a result of financial close and review procedures, the risk that expanding into a new biologics manufacturing capability may distract senior management’s focus on the company’s existing operations, the risk that the company may experience delays in hiring qualified individuals into the cell and gene therapy business, the risk that the company may experience delays in engaging customers for the cell and gene therapy business, and the risk that the cell and gene therapy business may not become profitable for several years, if ever. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2023, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this press release except as may be required by law. 

 

Contacts:

Stephanie Diaz (Investors) Tim Brons (Media)
Vida Strategic Partners Vida Strategic Partners
415-675-7401 415-675-7402
sdiaz@vidasp.com tbrons@vidasp.com
 EX-99.1 3 avid_ex9902.htm PRESS RELEASE ANNOUNCING CONVERTIBLE NOTE OFFERING, DATED MARCH 6, 2024

Exhibit 99.2

 

 

Avid Bioservices Announces Proposed Private Placement of Convertible Notes

 

TUSTIN, Calif., March 6, 2024 -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 (the “2029 Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The company expects to price the Offering before open of market on March 7, 2024.

 

The 2029 Notes will represent senior unsecured obligations of the company and will accrue interest payable semiannually in arrears. Upon conversion, the company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the Offering.

 

The company expects to use the net proceeds from the Offering (i) to repurchase for cash a portion of its 1.250% Exchangeable Senior Notes due 2026 (the “2026 Notes”) in privately negotiated transactions from certain noteholders and (ii) to the extent there are 2026 Notes outstanding after such repurchase, to repay in full any remaining outstanding 2026 Notes by depositing the required payoff amount with the trustee under the indenture of the 2026 Notes.

 

In connection with the repurchase or repayment of the 2026 Notes, the company expects to unwind its capped call transactions with respect to the 2026 Notes with the applicable counterparties. In connection with any such termination, the company expects the counterparties to such capped call transactions and/or their respective affiliates will unwind various derivatives with respect to the company’s common stock and/or sell shares of the company’s common stock concurrently with such termination. This activity could decrease the market price of the company’s common stock at that time.

 

The 2029 Notes and any shares of the company’s common stock issuable upon conversion of the 2029 Notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.

 

This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction. Further, this press release is not an offer to repurchase the 2026 Notes. As described in the Current Report on Form 8-K filed by the company on March 6, 2024, all of the 2026 Notes have been accelerated and became due and payable pursuant to an acceleration notice the company received from a holder of the 2026 Notes on February 29, 2024.

 

Forward-Looking Statements

 

Statements in this press release, which are not purely historical, including statements regarding the timing, size and expected completion of the offering of 2029 Notes, the expected unwind of the company’s capped call transactions with respect to the 2026 Notes, the use of proceeds from the offering, and other statements that are not statements of historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, those related to market and other conditions; the risk that the conditions to the closing of the proposed offering are not satisfied; and other risks and uncertainties that are described in the Risk Factors section of our annual report on Form 10-K for the fiscal year ended April 30, 2023, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this press release except as may be required by law.

 

Contacts:    
Stephanie Diaz (Investors) Tim Brons (Media)  
Vida Strategic Partners Vida Strategic Partners  
415-675-7401 415-675-7402  
sdiaz@vidasp.com tbrons@vidasp.com  

 

 

 EX-99.1 4 avid_ex9903.htm PRESS RELEASE ANNOUNCING PRICING OF CONVERTIBLE NOTE OFFERING, DATED MARCH 6, 2024

Exhibit 99.3

 

 

Avid Bioservices Announces Pricing of Private Placement of Convertible Notes

 

TUSTIN, Calif., March 6, 2024 -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). In connection with the offering, the company entered into private placement purchase agreements with the several purchasers, each of whom is a “qualified institutional buyer” within the meaning of Rule 144A promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The closing of the offering is subject to customary closing conditions and is expected to take place on March 12, 2024.

 

The 2029 Notes will represent senior unsecured obligations of the company and will accrue interest payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2024. The notes will mature on March 1, 2029, unless earlier converted or repurchased.

 

Before September 1, 2028, holders will have the right to convert their 2029 Notes only upon the satisfaction of specified conditions and during certain periods. On or after September 1, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2029 Notes at any time. Upon conversion, the company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The conversion rate for the 2029 Notes will initially be 101.1250 shares of the company’s common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $9.89 per share of the company’s common stock). The initial conversion price represents a premium of approximately 12.5% over the last reported sale price of $8.79 per share of the company’s common stock on March 6, 2024. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued or unpaid interest.

 

The 2029 Notes are not redeemable and no sinking fund is provided for the 2029 Notes. If the company undergoes a “fundamental change” (as defined in the indenture that will govern the 2029 Notes), then, subject to certain conditions and limited exceptions, holders may require the company to repurchase for cash all or any portion of their 2029 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events that occur prior to the maturity date, the company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2029 Notes in connection with such a corporate event.

 

The company expects to use the net proceeds from the Offering (i) to repurchase for cash a portion of its 1.250% Exchangeable Senior Notes due 2026 (the “2026 Notes”) in privately negotiated transactions from certain noteholders and (ii) to the extent there are 2026 Notes outstanding after such repurchase, to repay in full any remaining outstanding 2026 Notes by depositing the required payoff amount with the trustee under the indenture of the 2026 Notes.

 

The 2029 Notes and any shares of the company’s common stock issuable upon conversion of the 2029 Notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.

 

This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction. Further, this press release is not an offer to repurchase the 2026 Notes. As described in the Current Report on Form 8-K filed by the company on March 6, 2024, all of the 2026 Notes have been accelerated and became due and payable pursuant to an acceleration notice the company received from a holder of the 2026 Notes on February 29, 2024.

 

Forward-Looking Statements

 

Statements in this press release, which are not purely historical, including statements regarding the timing, size and expected completion of the offering of 2029 Notes, the use of proceeds from the offering, and other statements that are not statements of historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, those related to market and other conditions; the risk that the conditions to the closing of the proposed offering are not satisfied; and other risks and uncertainties that are described in the Risk Factors section of our annual report on Form 10-K for the fiscal year ended April 30, 2023, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this press release except as may be required by law.

 

Contacts:    
Stephanie Diaz (Investors) Tim Brons (Media)  
Vida Strategic Partners Vida Strategic Partners  
415-675-7401 415-675-7402  
sdiaz@vidasp.com tbrons@vidasp.com  

 

 EX-101.SCH 5 cdmo-20240306.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 cdmo-20240306_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 cdmo-20240306_pre.xml XBRL PRESENTATION FILE GRAPHIC 8 image_001.jpg GRAPHIC begin 644 image_001.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 06, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 06, 2024
Entity File Number 001-32839
Entity Registrant Name AVID BIOSERVICES, INC.
Entity Central Index Key 0000704562
Entity Tax Identification Number 95-3698422
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 14191 Myford Road
Entity Address, City or Town Tustin
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92780
City Area Code (714)
Local Phone Number 508-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol CDMO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://avidbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports avid_8k.htm cdmo-20240306.xsd cdmo-20240306_lab.xml cdmo-20240306_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "avid_8k.htm": { "nsprefix": "CDMO", "nsuri": "http://avidbio.com/20240306", "dts": { "inline": { "local": [ "avid_8k.htm" ] }, "schema": { "local": [ "cdmo-20240306.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cdmo-20240306_lab.xml" ] }, "presentationLink": { "local": [ "cdmo-20240306_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://avidbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "avid_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "avid_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://avidbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001683168-24-001367-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-001367-xbrl.zip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end XML 19 avid_8k_htm.xml IDEA: XBRL DOCUMENT 0000704562 2024-03-06 2024-03-06 iso4217:USD shares iso4217:USD shares false 0000704562 8-K 2024-03-06 AVID BIOSERVICES, INC. DE 001-32839 95-3698422 14191 Myford Road Tustin CA 92780 (714) 508-6100 false false false false Common Stock, $0.001 par value per share CDMO NASDAQ false